AstraZeneca
Drugmaker AstraZeneca PLC (NYSE: AZN) has seen a share price decline of about 3% over the past 12 months. For the year to date, the shares are up nearly 5%. Last month, AstraZeneca’s recently acquired Alexion itself acquired struggling biotech LogicBio Therapeutics for $2.07 a share (around $68 million). That was a 666% premium over LogicBio’s most recent closing price. The acquisition was expected to close by the middle of November, and it has lifted the share price by about 11% since it was announced in early October.
Analysts are mostly bullish on the stock, with 21 of 26 brokerages having a Buy or Strong Buy rating and four more rating the shares at Hold. At a recent price of around $61.10 a share, the upside potential based on a median price target of $138.97 is about 127%. At the high price target of $199.37, the upside potential is 226%.
For the company’s fiscal third quarter, analysts are forecasting revenue of $10.86 billion, which would be an increase of 0.8% sequentially and an increase of 10% year over year. Adjusted EPS are tabbed to come in at $1.52, down by about 11.7% sequentially but 40.7% higher year over year. For the full 2022 fiscal year, the current revenue estimate is $44.28 billion, up 18.4%, and the EPS estimate is $6.64, up about 25.5%.
AstraZeneca stock trades at 18.5 times expected 2022 EPS, 16.2 times estimated 2023 earnings of $7.54 and 13.7 times estimated 2024 earnings of $8.96 per share. The stock’s 52-week trading range is $52.65 to $71.70. AstraZeneca pays an annual dividend of $1.45 (yield of 2.42%). Total shareholder return for the past year was negative 0.8%.
Nio
China-based electric vehicle maker Nio Inc. (NYSE: NIO) has lost about 75% from its share price over the past 12 months. Shares posted a new 52-week low about two weeks ago, dropping nearly 39% in October alone. Investors were wary of the impact of closing two assembly plants due to China’s zero-covid policy. October production results turned out much better than many expected, and that put a charge under the stock, which trades something like a meme stock to begin with.
There are 28 analyst ratings on Nio’s stock, and 26 are Buy or Strong Buy. At a share price of around $11.00, the upside potential based on a median price target of $26.99 is around 145%. At the high target of $64.59, the upside potential is approaching 500%.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
